GLP1R and type 2 diabetes mellitus: This study aimed to evaluate the efficacy of novel antidiabetic non-insulin drugs, respectively, SGLT-2i, and GLP-1 RA versus metformin, in reaching an HbA1c < 7 % and a BWR of at least 5%, in patients with T2DM in a real-life setting.